 Mustang Bio Inc NASDAQ: MBIO has been awarded a grant of approximately 2 million from the National Cancer Institute of the National Institutes of Health NIH. The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia. 